Back
Speaker illustration

Professor Li-Ming Gan

Early Clinical Development, Research and Early Development, CVRM, BioPharmaceuti, Gothenburg (Sweden)

Presentations

Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration

Event: ESC Congress 2023

Topic: Anticoagulants

Session: Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Access
Like
Thumbnail

RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys

Event: ESC Congress 2023

Topic: Lipid-Lowering Agents

Session: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources